Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

famitinib

famitinib is a vascular endothelial growth factor receptor 3 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — famitinib
Class
—
Route
—
Patents
0
Programs
1
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

famitinib is a vascular endothelial growth factor receptor 3 inhibitor.

Key facts

INN famitinib
Mechanism Vascular endothelial growth factor receptor 3 inhibitor
Target Platelet-derived growth factor receptor

Mechanism of action

Vascular endothelial growth factor receptor 3 inhibitor

Primary target: Platelet-derived growth factor receptor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Famitinib Phase 2 · Chinese Academy of · Non-Small Cell Lung Cancer (NSCLC)

Related & competitor drugs

Browse all drugs
  1. midostaurin Antineoplastic and immunomodulating agents (L01)
  2. sorafenib tosylate Vascular endothelial growth factor receptor inhibitor
  3. avapritinib Antineoplastic and immunomodulating agents (L01)
  4. becaplermin Dermatologicals (D03)
  5. olaratumab Antineoplastic and immunomodulating agents (L01)
  6. ripretinib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is famitinib?

famitinib is a vascular endothelial growth factor receptor 3 inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.